ATE168267T1 - Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten - Google Patents

Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Info

Publication number
ATE168267T1
ATE168267T1 AT93310599T AT93310599T ATE168267T1 AT E168267 T1 ATE168267 T1 AT E168267T1 AT 93310599 T AT93310599 T AT 93310599T AT 93310599 T AT93310599 T AT 93310599T AT E168267 T1 ATE168267 T1 AT E168267T1
Authority
AT
Austria
Prior art keywords
fatty acid
compositions containing
unsaturated fatty
cholesterol esters
containing cholesterol
Prior art date
Application number
AT93310599T
Other languages
German (de)
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE168267T1 publication Critical patent/ATE168267T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Optical Recording Or Reproduction (AREA)
AT93310599T 1993-01-06 1993-12-29 Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten ATE168267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939300125A GB9300125D0 (en) 1993-01-06 1993-01-06 Compositions containing esters of unsaturated fatty acids

Publications (1)

Publication Number Publication Date
ATE168267T1 true ATE168267T1 (de) 1998-08-15

Family

ID=10728334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93310599T ATE168267T1 (de) 1993-01-06 1993-12-29 Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Country Status (17)

Country Link
US (1) US5604216A (OSRAM)
EP (1) EP0606012B1 (OSRAM)
JP (1) JPH06234644A (OSRAM)
KR (1) KR940018088A (OSRAM)
CN (1) CN1096197A (OSRAM)
AT (1) ATE168267T1 (OSRAM)
AU (1) AU673555B2 (OSRAM)
CA (1) CA2112824A1 (OSRAM)
DE (1) DE69319710T2 (OSRAM)
DK (1) DK0606012T3 (OSRAM)
ES (1) ES2119871T3 (OSRAM)
GB (1) GB9300125D0 (OSRAM)
MY (1) MY110765A (OSRAM)
NO (1) NO940035D0 (OSRAM)
NZ (1) NZ250583A (OSRAM)
RU (1) RU2142468C1 (OSRAM)
ZA (1) ZA9425B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US5892068A (en) * 1998-08-25 1999-04-06 Mcneil-Ppc, Inc. Preparation of sterol and stanol-esters
NZ333817A (en) * 1998-08-25 2000-09-29 Mcneil Ppc Inc Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
JP2000355538A (ja) * 1999-04-15 2000-12-26 Kanegafuchi Chem Ind Co Ltd ペルオキシゾーム活性化剤応答性受容体アゴニスト
EP1175901B1 (en) * 1999-04-15 2006-05-31 Kaneka Corporation Peroxisome activator-responsive receptor agonists
US6998501B1 (en) * 1999-08-30 2006-02-14 Ocean Nutrition Canada Limited Nutritional supplement for lowering serum triglyceride and cholesterol levels
AU6813700A (en) * 1999-08-30 2001-03-26 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
DK1121928T3 (da) * 2000-01-31 2008-03-17 Haerting S A Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider
KR20010091499A (ko) * 2000-03-16 2001-10-23 김용범 레이저 그래픽 디스플레이 장치
JP4594489B2 (ja) * 2000-03-31 2010-12-08 備前化成株式会社 特異的殺癌細胞剤及びこれを配合してなる組成物
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
MXPA05008216A (es) * 2003-01-31 2005-10-05 Procter & Gamble Medios para mejorar la apariencia del tejido queratinoso mamifero.
CN101195649A (zh) * 2003-04-02 2008-06-11 美国政府健康及人类服务部 含胆固醇的化合物以及其用作针对伯氏疏螺旋体(Borrelia burgdorferi)的免疫原的应用
US20070098787A1 (en) * 2003-06-20 2007-05-03 Mochida Pharmaceutical Co., Ltd. Composition for preventing and treating varicose veins of lower extremities
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
JP2007536259A (ja) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド 活性薬剤の送達のための粒子
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
CN101262863B (zh) * 2005-07-08 2016-08-31 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
US20080110624A1 (en) * 2005-07-15 2008-05-15 Halliburton Energy Services, Inc. Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) * 2005-12-13 2007-06-14 Anna Petroni Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SG173612A1 (en) 2009-02-10 2011-09-29 Amarin Pharma Inc Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
SMT201800047T1 (it) 2009-04-29 2018-03-08 Amarin Pharmaceuticals Ie Ltd Composizione farmaceutica stabile e metodi di utilizzo della stessa
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
KR101293278B1 (ko) * 2009-10-29 2013-08-09 주식회사 한독 신규 혈관누출 차단제
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
UA128280C2 (uk) 2012-06-29 2024-05-29 Амарін Фармасьютікалз Айрленд Лімітед Спосіб зменшення ризику розвитку серцево-судинної події у суб'єкта, що одержує терапію статином
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
CA2886024C (en) * 2012-10-11 2019-10-29 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) * 2016-12-08 2017-11-01 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するための組成物
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6491293B2 (ja) * 2017-10-04 2019-03-27 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
ES2983568T3 (es) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto
JP6728425B2 (ja) * 2019-02-28 2020-07-22 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのクリーム、ローション、又はゲルの組成物
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH Atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003175A1 (en) * 1981-03-13 1982-09-30 Arakawa Yoshio Water-soluble cholesterol derivatives
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
SU1456442A1 (ru) * 1987-04-03 1989-02-07 Житомирский Государственный Педагогический Институт Им.И.Франко (Холестерилоксикарбонилметил)трифенилфосфонийхлорид в качестве полупродукта в синтезе холестериловых эфиров непредельных карбоновых кислот

Also Published As

Publication number Publication date
RU2142468C1 (ru) 1999-12-10
DE69319710T2 (de) 1999-03-11
NZ250583A (en) 1997-08-22
EP0606012A1 (en) 1994-07-13
AU5276393A (en) 1994-07-14
DK0606012T3 (da) 1999-04-19
NO940035L (OSRAM) 1994-07-07
CA2112824A1 (en) 1994-07-07
AU673555B2 (en) 1996-11-14
GB9300125D0 (en) 1993-03-03
EP0606012B1 (en) 1998-07-15
NO940035D0 (no) 1994-01-05
US5604216A (en) 1997-02-18
ES2119871T3 (es) 1998-10-16
CN1096197A (zh) 1994-12-14
KR940018088A (ko) 1994-08-16
JPH06234644A (ja) 1994-08-23
ZA9425B (en) 1994-08-19
MY110765A (en) 1999-03-31
DE69319710D1 (de) 1998-08-20

Similar Documents

Publication Publication Date Title
ATE168267T1 (de) Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten
RU94000061A (ru) Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
ATE106867T1 (de) 13-trans-retinsäureester.
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
AU7053494A (en) Method of treating coronary vascular disease using docosahexaenoic acid
CA2144312A1 (en) Unsaturated aliphatic dicarboxylic acids
DE69312579D1 (de) Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
ATE138639T1 (de) L-carnitin- und alkanoyl-l-carnitin-ester mit glykolsäure oder ihre ester und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von dermatosen
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
AU554413B2 (en) Linoleic acid and essential fatty acid compositions as
FI883310A0 (fi) Rengoeringsmedelkomposition och dess anvaendning.
DE3760876D1 (en) Cyclohexane-, cyclohexene- and cyclohexadiene, bicycloû2.2.1¨heptane and bicyclo û2.2.1¨heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DE3851938D1 (de) Polyaromatische Ester von makroliden Antibiotika und linkosamiden Antibiotika, Verfahren zu ihrer Herstellung und diese enthaltenden pharmazeutischen und kosmetischen Zusammensetzungen.
ATE113290T1 (de) Nicht gesättigte cycloaliphatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
ES2191671T3 (es) Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.
RU94002319A (ru) Триглицериды

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee